Abstract
Backgroud
Multiple myeloma (MM) is an incurable plasma cell malignancy in the bone marrow (BM), while immunoglobulin D type of MM (IgD MM) is a very rare but most severe subtype in all MM cases. Therefore, systemic study on IgD MM is purposeful to disclose the recurrent and refractory features in both IgD and other types of MM, and beneficial to the development of potent therapeutic strategy on MM.
Methods
Agilent SBC-ceRNA microarray chips were employed to examine 3 normal plasma cell samples (NPCs), 5 lgD MM samples and 5 lgG MM samples, respectively. Sanger sequencing, RNase R digestion and qPCR assays were used to detect the existence and expression of circHNRNPU. BaseScope™ RNA ISH assay was performed to test circHNRNPU levels in paraffin-embedded MM tissues. The protein encoded by circHNRNPU was identified by LC-MS/MS, which was named as circHNRNPU_603aa. The function of circHNRNPU_603aa on cellular proliferation and cell cycle was assessed by MTT test, colony formation assay, flow cytometry and MM xenograft mouse model in vivo. RIP-seq, RIP-PCR and WB analysis for ubiquitination were performed to explore the potential mechanism of circHNRNPU_603aa in MM. Exosomes were isolated from the culture supernatant of MM cells by ultracentrifugation and characterized by Transmission Electron Microscope and WB confirmation of exosomes markers Alix and CD9.
Results
CircHNRNPU was one of the top most abundant and differentially expressed circRNA in IgD MM relative to lgG and NPCs samples. Increased circHNRNPU was associated with poor outcomes in four independent MM patient cohorts. Intriguingly, MM cells secreted circHNRNPU, which encoded a protein named as circHNRNPU_603aa. Overexpressed circHNRNPU_603aa promoted MM cell proliferation in vitro and in vivo, in contrast knockdown of circHNRNPU_603aa by siRNA abrogated these effects. Due to circHNRNPU_603aa including RNA-binding RGG-box region, it regulated SKP2 exon skip**, thereby competitively inhibited c-Myc ubiquitin so as to stabilize c-Myc in MM. MM cells secreted circHNRNPU through exosomes to interfere with various cells in the BM microenvironment.
Conclusion
Our findings demonstrate that circHNRNPU_603aa is a promising diagnostic and therapeutic marker in both MM cells and BM niche.
Similar content being viewed by others
Background
Multiple myeloma (MM) is a molecularly and cytogenetically heterogeneous hematological malignancy heavily dependent on bone marrow (BM) microenvironment, which is characterized by the clonal proliferation of malignant plasma cells [1]. Despite the advanced development of targeted drugs, such as immune modulators and proteasome inhibitors, have greatly improved outcomes of MM patients over the decades, MM remains incurable [2, 3]. As a most severe type among all the subtypes of MM, immunoglobulin D multiple myeloma (IgD MM) is very rare comprising only 1 to 2% of all MM cases featured by diagnosis in relatively young patients, and often accompanied by multiple adverse prognosis, such as extraosseous lesions, renal failure, extramedullary involvement, amyloidosis [4, 5]. The most distinguish characteristic of lgD MM is poor outcome of refractory status, only 13 ~ 21-month overall survival (OS) compared with 3 ~ 6-year overall median survival in common MM [6,7,8]. Therefore, systemic investigation on IgD MM is purposeful to reveal the recurrent and refractory features in both IgD and other types of MM, and beneficial to develop potent therapeutic strategy on MM.
The advanced research achievement of the microenvironmental interactions between MM cells and the BM niche, and their roles in the progression of disease and acquisition of drug resistance, has promoted the development of novel therapeutic drugs for MM treatment [9,10,11,12]. The intercellular interaction in BM niche through exosomes and circular RNAs (circRNAs) attracts extensive attention [13]. CircRNAs, back-spliced products of exonic or intronic sequence of precursor mRNA (pre-mRNA), are a fascinating class of conserved single-stranded RNA molecules [14,15,16]. It has been reported that circRNAs act as essential players in cancer initiation, progression and drug resistance [17, 18]. In particular, circRNAs may influence tumor microenvironment through intercellular communication due to its abundance in exosomes and human body fluids [19]. Therefore, circRNAs are now being considered as promising biomarkers for cancer [20]. Many studies have suggested that circRNAs are translatable, which are translated into previously unknown protein isoforms [5A). We subsequently performed Gene Ontology (GO) function significance enrichment analysis for better understanding of the potential biological effects of these circHNRNPU_603aa-regulated AS events, which were mainly related to cell composition, binding and other functions (Fig. 5B). The pathway enrichment analysis of these circHNRNPU_603aa regulated AS events revealed that their molecular function was centered on ubiquitin mediated proteolysis (Fig. 5C). To further identify the regulation mechanism of circHNRNPU_603aa for AS, we performed de novo discovery of the circHNRNPU_603aa binding motif using the overlap exon sequences of circHNRNPU_603aa regulated AS events and circHNRNPU_603aa binding transcripts from RIP-seq data. Among these circHNRNPU_603aa regulated AS events, the expression of SKP2 exon 5 skip** splice variants was significantly increased in circHNRNPU_603aa-OE cells and ranked the top of AS events (Fig. 5D). SKP2 encodes a member of the F-box protein family, which is characterized by F-box nearly 40 amino acid motif. The F-box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCF complex, which plays an important role in ubiquitination [35,36,37] and might be related to the molecular function of circHNRNPU_603aa.
Identification of circHNRNPU_603aa-regulated AS events. A Number of AS events in each category. B GO Molecular Function enrichment of circHNRNPU_603aa-regulated AS genes. C The pathway enrichment analysis of above genes revealed that their molecular function was centered on ubiquitin mediated proteolysis. D The expression of SKP2 exon 5 skip** splice variants was significantly increased by increased circHNRNPU_603aa and ranked top of the circHNRNPU_603aa-regulated AS events. E-G Survival proportions of patients corresponding to different probes of SKP2 in APEX cohort. 203626_s_at was related to better survival compared with other probes. H-J The expression of SKP2-NM_001243120.2 in circHNRNPU_603aa-OE and si-circHNRNPU_603aa cells relative to control cells. A two-tailed Student’s t-test was utilized to evaluate statistical significance. K-L Overexpression of circHNRNPU-603aa directly upregulated SKP2-NM_001243120.2 and downregulated SKP2-NM_005983.4 detected by RIP-qPCR. The data are presented as mean ± SD.*p < 0.05, **p < 0.01, ***p < 0.001
In particular, we found that the probe 203626_s_at, designed on the basis of SKP2- NM_005983.4 splicing variant, was associated with better overall survival compared with other probes in APEX cohort (Fig. 5E-G). We detected the expressions of the two isoforms SKP2-NM_005983.4 and SKP2-NM_001243120.2 in circHNRNPU_603aa-OE cells by qPCR. Interestingly, the expression of SKP2-NM_001243120.2 was increased in circHNRNPU_603aa-OE cells relative to WT cells in both ARP1 and CAG cells (Fig. 5H-I). In comparison, the expression of SKP2-NM_001243120.2 was significantly decreased in si-circHNRNPU_603aa cells compared with NC cells treated with non-targeted siRNA (Fig. 5H-J). Furthermore, we adopted RIP-PCR to confirm circHNRNPU-603aa-regulated exon skip** in MM cells using HA antibody as bait. It was found that circHNRNPU-603aa directly bound to the endogenous SKP2-NM_001243120.2, and elevated circHNRNPU-603aa increased SKP2-NM_001243120.2 expression compared with WT cells (Fig. 5K-L). Collectively, we inferred that circHNRNPU-603aa regulated SKP2 exon skip**, thereby spliced NM_005983.4 into NM_001243120.2, suggesting that circHNRNPU-603aa-regulated SKP2 exon skip** might play an important role in promoting MM progression.
Aberrant splicing of SKP2 contributes to the reduction of c-Myc ubiquitin
To further understand the significance of circHNRNPU-603aa-regulated SKP2 exon skip** and clarify the function of the two splicing isoforms of SKP2 in MM, we first designed a siRNA targeting SKP2-NM_001243120.2 (Fig. 6A-B). As shown in Fig. 6C, the cell proliferation was decreased in si-SKP2-NM_001243120.2 cells relative to NC cells. Since SKP2 is associated with SCF complex participating in c-Myc proteosomal degradation [36], our WB analysis identified that c-Myc expression was decreased in si-SKP2-NM_001243120.2 cells relative to NC cells (Fig. 6D).
Aberrant splicing of SKP2 contributes to the reduction of c-Myc ubiquitin. A Graphic illustration of siRNA targeting SKP2-NM_001243120.2. B qPCR analysis of SKP2-NM_001243120.2 expression in ARP1 and CAG cells. C Inhibition of SKP2-NM_001243120.2 prominently decreased cell proliferation in ARP1 and CAG cells detected by MTT. D WB showed that c-Myc expression was decreased in si-SKP2-NM_001243120.2 cells compared with NC cells. E Graphic illustration of SKP2-NM_005983.4-OE and SKP2-NM_001243120.2-OE plasmids linked with HA and FLAG tag, respectively. F SKP2-NM_001243120.2 FLAG-tagged isoform upregulated c-Myc expression while the SKP2-NM_005983.4 HA-tagged isoform downregulated c-Myc expression in ARP1 and CAG cells. G WB confirmed that c-Myc expression was increased in circHNRNPU_603aa-OE cells and downregulated in si-circHNRNPU_603aa cells. H Co-IP experiment indicated an interaction between SKP2 and c-Myc in MM cells. I SKP2-NM_001243120.2 FLAG-tagged isoform or SKP2-NM_005983.4 HA-tagged isoform overexpressed cells were treated with MG132 for 12 h. An ubiquitination assay was performed using anti-c-Myc magnetic beads, and the ubiquitylated proteins were detected by Ub antibody. The data are presented as mean ± SD.*p < 0.05, **p < 0.01, ***p < 0.001
As the protein encoded by SKP2-NM_001243120.2 lacks F-Box domain compared with the protein encoded by SKP2-NM_005983.4, which is a component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex mediating the ubiquitination and subsequent proteasomal degradation of c-Myc [36], we further constructed SKP2-NM_005983.4-OE and SKP2-NM_001243120.2-OE plasmids linked with HA and FLAG tags respectively to examine the molecular function of the two splicing isoforms of SKP2 (Fig. 6E). Intriguingly, SKP2-NM_001243120.2 FLAG-tagged isoform upregulated c-Myc expression, while SKP2-NM_005983.4 HA-tagged isoform downregulated c-Myc expression (Fig. 6F). In addition, c-Myc expression was increased in circHNRNPU_603aa-OE cells and decreased in si-circHNRNPU_603aa cells relative to control cells (Fig. 6G). Co-IP assay validated the interaction between SKP2 and c-Myc in MM cells (Fig. 6H). After MM cells were incubated with 20 μM MG132 (a proteasome inhibitor) for 12 h, the ubiquitination was significantly suppressed in SKP2-NM_001243120.2-OE cells compared with SKP2-NM_005983.4-OE cells (Fig. 6I). Therefore, it was speculated that circHNRNPU-603aa mediated the alternative splicing of SKP2 to upregulate circHNRNPU-603aa splicing isoform SKP2-NM_001243120.2, and subsequently competitively inhibited c-Myc ubiquitination and stabilized c-Myc expression (Fig. 6H-I).
MM cells secrete circHNRNPU into the BM microenvironment through exosomes
It is well known that the BM microenvironment is especially important for the oncogenic growth of MM cells, and many studies have explored the effect of circRNAs on the BM microenvironment through intercellular communication [38]. CircRNAs are abundant and stable in exosomes serving as potential biomarkers for cancer detection and transferring biological activity to recipient cells [39]. We extracted the exosomes from the culture supernatant of ARP1 and CAG cells, which were identified by TEM method (Fig. 7A) and WB confirmation of exosomes markers Alix and CD9 (Fig. 7B). As expected, circHNRNPU was detected in exosomes (Fig. 7C-D). We cocultured WT ARP1, WT CAG, HEK-293 and HS-5 cells with CAG circHNRNPU-OE cells using transwell (Fig. 7E), then we found that all the cocultured cells expressed circHNRNPU (Fig. 7F). Under the treatment with GW4869, a well-recognized exosomes inhibitor that could reduce exosomes release [40], circHNRNPU did not migrate into cells in the BM, indicating that circHNRNPU was secreted by MM cells through exosomes (Fig. 7F). Furthermore, application of HA antibody and MS analysis confirmed the specific peptide fragments from circHNRNPU_603aa in the cocultured cells (Fig. 7G-H). After ARP1 and CAG WT cells were cocultured with CAG circHNRNPU-OE cells for 12 h, 24 h, 48 h, IF staining for HA and DAPI showed that the cocultured cells expressed circHNRNPU_603aa in a time-dependent manner (Fig. 7I-J). As depicted in Fig. 7K, the proliferation rate of cocultured ARP1 and CAG cells was significantly increased (p < 0.01) relative to non-cocultured WT cells. Cell cycle analysis also indicated an increased proportion of G2/M phase in cocultured ARP1 and CAG cells relative to non-cocultured cells (Fig. 7L). Summarily, we demonstrated that MM cells could secrete circHNRNPU through exosomes to interfere with various cells in the BM microenvironment (Fig. 8).
MM cells secrete circHNRNPU into the BM microenvironment through exosomes. A Transmission electron microscopy (TEM) was used to characterize exosomes from the culture supernatant of ARP1 and CAG cells. B WB analysis showed the presence of exosome markers Alix and CD9. C-D RNA levels of circHNRNPU and linear HNRNPU ± RNase R were determined by RT-PCR and qRT-PCR. E Graphic illustration of cocultured WT ARP1, CAG, HEK-293, HS-5 cells with the CAG circHNRNPU-OE cells using transwell. F qPCR analysis of circHNRNPU expression in ARP1, CAG, HEK-293, HS-5 cells cocultured with CAG circHNRNPU-OE cells. G WB analysis of circHNRNPU_603aa expression in ARP1, CAG, HEK-293, HS-5 cells cocultured with CAG circHNRNPU-OE cells using HA tag antibody. H The specific peptides from circHNRNPU_603aa were identified by mass spectrometry analysis. I-J Representative confocal images for HA and DAPI showed that circHNRNPU_603aa expression was in time-dependent manner in (I) ARP1 and (J) CAG cells. K MTT assay indicated higher cell proliferation rate of cocultured circHNRNPU-OE MM cells than WT cells. L Cell cycle assay exhibited higher G2/M proportion of cocultured circHNRNPU-OE MM cells than WT cells. The data are presented as mean ± SD.*p < 0.05, **p < 0.01, ***p < 0.001
Discussion
MM remains an incurable hematologic malignancy due to adverse features, clonal heterogeneity and BM dependency, in which IgD MM is a very rare but most severe subtype [6]. In all MM cases, the low prevalence and insensitivity to diagnostic methods of IgD MM make it intractable [7]. Therefore, effective therapeutic strategies to target both MM cells and BM niche are of great importance to disclose the recurrent and refractory features in IgD and other types of MM. Diagnosis of IgD MM is difficult, since IgD presents minimal or even undetectable M-protein spikes via serum protein electrophoresis (SPEP) [41, 42]. Thus, some cases manifest as hypogammaglobulinemia or present normal SPEP results, which may lead to misdiagnosis of patients in this subgroup [43, 44]. Many studies have focused on IgD MM and circRNAs, which are novel RNA molecules with significant biological functions, therapeutic and diagnostic significance, especially on cellular interaction in the BM niche [45, 46].
In this study, we employed Agilent SBC-ceRNA microarray chips to identify circHNRNPU as the most abundantly and differentially expressed circRNA in IgD MM samples relative to IgG MM samples and NPCs. BaseScopeTM RNA ISH follows a similar workflow and principle to the well-established novel RNAscopeTM RNA ISH technique used for detection of RNA in situ, with hybridization and amplification of target RNA [47, 54]. Changes in clonal dynamics over time during MM progression and drug therapy lead to drug resistance and relapse [55]. Our work has explained that MM cells secrete circHNRNPU into BM microenvironment through exosomes to influence the surrounding cells, and the exact composition and distribution of circRNAs contribute to the clonal evolution. Here, we infer that circRNAs shuttle may play a vital role in clonal competition and therefore lead to treatment failure and relapse in IgD and other types of MM.
The common function model of circRNAs is serving as a miRNA sponge and interacts with associated proteins [67]. Patients with c-Myc translocation have worse progression-free survival (PFS) and overall survival (OS) [68]. In addition, c-Myc alteration is proposed to be a trigger of monoclonal gammopathy of undetermined significance (MGUS) to MM transition [5], and it is regarded as a late genomic event responsible for tumor progression.
Conclusions
Our findings provide a novel and mechanistic insight into circHNRNPU_603aa which is secreted into the BM microenvironment and promotes MM progression through regulating SKP2 exon skip** and subsequently competitively inhibiting c-Myc ubiquitin. CircHNRNPU_603aa may serve as a promising diagnostic marker and potential therapeutic target in MM.
Availability of data and materials
All data in our study are available upon reasonable request. The RIP-seq data and Agilent SBC-ceRNA microarray chips data were deposited in GEO (GSE 174501 and GSE 174510).
Abbreviations
- APEX:
-
Assessment of Proteasome Inhibition for Extending Remission
- BM:
-
Bone marrow
- GEO:
-
Gene expression omnibus
- GEP:
-
Gene expression profiling
- IF:
-
Immunofluorescence
- IRES:
-
Internal ribosome entry site
- MS:
-
Mass spectrometry
- MM:
-
Multiple myeloma
- MGUS:
-
Monoclonal gammopathy of undetermined significance
- ORF:
-
Open Reading Frame
- OS:
-
Overall survival
- PFS:
-
Progression-free survival
- RIP-seq:
-
RNA Immunoprecipitation sequencing
- TT2:
-
Total therapy 2
- UPS:
-
Ubiquitin-proteasome system
- WGCNA:
-
Weighted gene correlation network analysis
References
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324–39.
Voelker R. Combination approved for advanced multiple myeloma. JAMA. 2019;322:393.
Wilcock P, Webster R. The multiple myeloma drug market. Nat Rev Drug Discov. 2019;18:579–80.
Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–208.
Wang W, Zhang C, Li Z, Gong M, Ma Y. Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma. BMC Cancer. 2018;18:650.
Kim M, Suh C, Lee D, Min C, Kim S, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22:411–6.
Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, et al. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21:1054–8.
Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, et al. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010;95:2126–33.
Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496.
Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, et al. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nat Commun. 2020;11:6037.
Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer - implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018;15:617–38.
Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches. Blood. 2019;133:1534–9.
Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129:2429–36.
Shi L, Liu B, Shen D, Yan P, Zhang Y, Tian Y, Hou L, Jiang G, Zhu Y, Liang Y, et al. A tumor-suppressive circular RNA mediates uncanonical integrin degradation by the proteasome in liver cancer. Science advances. 2021;7:13.
Wang L, Zhou Y, Jiang L, Lu L, Dai T, Li A, et al. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway. Mol Cancer. 2021;20:43.
Lyu L, Zhang S, Deng Y, Wang M, Deng X, Yang S, et al. Regulatory mechanisms, functions, and clinical significance of CircRNAs in triple-negative breast cancer. J Hematol Oncol. 2021;14:41.
Guarnerio J, Bezzi M, Jeong JC, Paffenholz SV, Berry K, Naldini MM, et al. Oncogenic role of fusion-circRNAs derived from Cancer-associated chromosomal translocations. Cell. 2016;165:289–302.
Fan Y, Wang J, ** W, Sun Y, Xu Y, Wang Y, et al. CircNR3C2 promotes HRD1-mediated tumor-suppressive effect via sponging miR-513a-3p in triple-negative breast cancer. Mol Cancer. 2021;20:25.
Hu W, Liu C, Bi Z, Zhou Q, Zhang H, Li L, et al. Comprehensive landscape of extracellular vesicle-derived RNAs in cancer initiation, progression, metastasis and cancer immunology. Mol Cancer. 2020;19:102.
Zhang M, Huang N, Yang X, Luo J, Zhang N. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018;37:1805-14.
Jiang T, **a Y, Lv J, Li B, Li Y, Wang S, et al. A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling. Mol Cancer. 2021;20:66.
Li J, Ma M, Yang X, Zhang M, Luo J, Zhou H, et al. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer. 2020;19:142.
**a X, Li X, Li F, Wu X, Zhang M, Zhou H, et al. Correction to: a novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. Mol Cancer. 2019;18:149.
Liang W, Wong C, Liang P, Shi M, Cao Y, Rao S, et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20:84.
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–8.
Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood. 2010;116:2543–53.
Yang H, Li X, Meng Q, Sun H, Wu S, Hu W, et al. CircPTK2 (hsa_circ_0005273) as a novel therapeutic target for metastatic colorectal cancer. Mol Cancer. 2020;19:13.
Yang Y, Guan D, Lei L, Lu J, Liu JQ, Yang G, et al. H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. Toxicol Appl Pharmacol. 2018;341:98–105.
Gagliardi M, Matarazzo MR. RIP: RNA Immunoprecipitation. Methods Mol Biol. 2016;1480:73–86.
Kim MK, Suh C, Lee DH, Min CK, Kim SJ, Kim K, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol. 2011;22:411–6.
**a X, Li X, Li F, Wu X, Zhang M, Zhou H, et al. A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. Mol Cancer. 2019;18:131.
Helbig R, Fackelmayer FO. Scaffold attachment factor a (SAF-A) is concentrated in inactive X chromosome territories through its RGG domain. Chromosoma. 2003;112:173–82.
Hadian K, Vincendeau M, Mausbacher N, Nagel D, Hauck SM, Ueffing M, et al. Identification of a heterogeneous nuclear ribonucleoprotein-recognition region in the HIV rev protein. J Biol Chem. 2009;284:33384–91.
Zhang B, Wang HY, Zhao DX, Wang DX, Zeng Q, ** JF, et al. The splicing regulatory factor hnRNPU is a novel transcriptional target of c-Myc in hepatocellular carcinoma. FEBS Lett. 2021;595:68–84.
Asmamaw M, Liu Y, Zheng Y, Shi X, Liu H. Skp2 in the ubiquitin-proteasome system: a comprehensive review. Med Res Rev. 2020;40:1920–49.
von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189–200.
Cai Z, Moten A, Peng D, Hsu CC, Pan BS, Manne R, et al. The Skp2 pathway: a critical target for Cancer therapy. Semin Cancer Biol. 2020;67:16–33.
Zhang Q, Wang W, Zhou Q, Chen C, Yuan W, Liu J, et al. Roles of circRNAs in the tumour microenvironment. Mol Cancer. 2020;19:14.
Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015;25:981–4.
Catalano M, O'Driscoll L. Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020;9:1703244.
Bla De J. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398–404.
Shimamoto Y. IgD myeloma: clinical characteristics and a new staging system based on analysis of Japanese patients. Cancer Detect Prev. 1995;19:426–35.
Jí S, Tichy M, Kovářová H. Two-dimensional gel electrophoresis of four serum samples from patients with IgD myeloma. Clin Chim Acta. 1993;218:149.
Arpin C, Bouteiller OD, Razanajaona D, Fugier-Vivier I, Briere F, Banchereau J, et al. The Normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, Cμ–Cδ switch, and λ light chain expression. J Exp Med. 1998;187:1169–78.
Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, et al. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021;20:84.
Tang X, Guo M, Ding P, Deng Z, Ke M, Yuan Y, et al. BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability. Signal Transduct Target Ther. 2021;6:361.
Sengal AT, Patch AM, Snell CE, Smith DS, Leung SCY, Talhouk A, et al. FGFR2c mesenchymal isoform expression is associated with poor prognosis and further refines risk stratification within endometrial Cancer molecular subtypes. Clin Cancer Res. 2020;26:4569–80.
**ao B, Zuo D, Hirukawa A, Cardiff RD, Lamb R, Sonenberg N, et al. Rheb1-independent activation of mTORC1 in mammary tumors occurs through activating mutations in mTOR. Cell Rep. 2020;31:107571.
Cowan CS, Renner M, De Gennaro M, Gross-Scherf B, Goldblum D, Hou Y, et al. Cell types of the human retina and its organoids at single-cell resolution. Cell. 2020;182:1623–1640 e1634.
Vo JN, Cieslik M, Zhang Y, Shukla S, **ao L, Zhang Y, et al. The landscape of circular RNA in Cancer. Cell. 2019;176:869–881 e813.
Bahn J, Zhang Q, Li F, Chan T, Lin X, Kim Y, et al. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin Chem. 2015;61:221–30.
Memczak S, Papavasileiou P, Peters O, Rajewsky N. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. Plos One. 2015;10:e0141214.
Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120:1067–76.
Paiva B, Perez-Andres M, Vidriales MB, Almeida J, de Las Heras N, Mateos MV, et al. Competition between clonal plasma cells and normal cells for potentially overlap** bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 2011;25:697–706.
Brioli A, Melchor L, Cavo M, Morgan GJ. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. Br J Haematol. 2014;165:441–54.
Yang Y, Gao X, Zhang M, Yan S, Sun C, **ao F, Huang N, Yang X, Zhao K, Zhou H, et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. J Natl Cancer Inst. 2018;110:304-15.
Pamudurti NR, Bartok O, Jens M, Ashwal-Fluss R, Stottmeister C, Ruhe L, et al. Translation of CircRNAs. Mol Cell. 2017;66:9–21 e27.
Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in Myogenesis. Mol Cell. 2017;66:22–37 e29.
Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629.
Abe N, Matsumoto K, Nishihara M, Nakano Y, Shibata A, Maruyama H, et al. Rolling circle translation of circular RNA in living human cells. Sci Rep. 2015;5:16435.
Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N (6)-methyladenosine. Cell Res. 2017;27:626–41.
Wang Y, Wang Z. Efficient backsplicing produces translatable circular mRNAs. RNA. 2015;21:172–9.
Agrawal AA, Yu L, Smith PG, Buonamici S. Targeting splicing abnormalities in cancer. Curr Opin Genet Dev. 2018;48:67–74.
Biamonti G, Catillo M, Pignataro D, Montecucco A, Ghigna C. The alternative splicing side of cancer. Semin Cell Dev Biol. 2014;32:30–6.
**ng S, Li Z, Ma W, He X, Shen S, Wei H, et al. DIS3L2 promotes progression of hepatocellular carcinoma via hnRNP U-mediated alternative splicing. Cancer Res. 2019;79:4923–36.
Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E. The functional impact of alternative splicing in Cancer. Cell Rep. 2017;20:2215–26.
Crawford L, Campbell D, Morgan J, Lawson M, Down J, Chauhan D, et al. The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. Oncogene. 2020;39:5001–14.
Jovanovic KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018;32:1295–306.
Acknowledgements
The authors acknowledge the participants who generously gave their help on the study. Especially, we thank Dr. **ng Cui and Wen Gao for providing clinical MM patient samples, and the experiment center for science and technology of Nan**g University of Chinese Medicine for providing the equipment.
Funding
This work was supported by National Key R&D Program of China (No. 2020YFA0509400); Natural Science Foundation of Jiangsu Province BK20200097 (to CG); National Natural Science Foundation of China 81870164 and 81372543 (to JD); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine); Jiangsu Postgraduate Research and Practice Innovation Program KYCX20_1479 (to X.T.) and KYCX21_1746 (to P.D.).
Author information
Authors and Affiliations
Contributions
YY, CG and JD designed the project, integrated the data and revised the manuscript; XT drafted the manuscript; XT, ZD, PD,WQ, YL, SG and YH performed the experiments and analyzed the data. All authors have read and approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
All animal experiments were performed in accordance with the Government-published recommendations for the Care and Use of Laboratory Animals, and were approved by the Institutional Ethics Review Boards of Nan**g University of Chinese Medicine (Ethics Registration no. 201905A003).
Consent for publication
All authors have agreed to publish this manuscript.
Competing interests
No potential conflicts of interest were disclosed.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Tang, X., Deng, Z., Ding, P. et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J Exp Clin Cancer Res 41, 85 (2022). https://doi.org/10.1186/s13046-022-02276-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13046-022-02276-7